Answers are grounded in this paper and cite their sources.
Experimental analysis demonstrated that synthetic flavonols inhibit TGF-βR1 and reduce pancreatic cancer cell growth, indicating a novel treatment approach.
Introduction: Pancreatic adenocarcinoma is a highly aggressive cancer with a poor prognosis and a five-year survival rate of just 13%. Its asymptomatic onset, rapid progression, and resistance to therapy make it challenging to treat. Transforming Growth Factor-β (TGF-β) signaling, particularly through TGF-β Receptor 1 (TGF-βR1/ALK-5), plays a major role in tumor progression by inducing Epithelial-Mesenchymal Transition (EMT), immune evasion, and apoptosis resistance. Targeting ALK-5 is a promising strategy for therapeutic intervention. Methods: Twenty-nine synthetic flavonols were designed to inhibit ALK-5 and docked using Schrodinger’s Glide XP. The compounds were synthesized via a green, one-pot method and characterized using 1H-NMR, 13CNMR, Mass Spectrometry, CHN analysis, and IR spectroscopy. The anti-cancer activity was evaluated against MiAPaCa-2 pancreatic cancer cells by measuring GI50, TGI, and LC50. ALK-5 inhibition was quantified using the ADP-Glo® Kinase Assay, assessing ATP transfer. Results: RFL-1 showed the strongest binding affinity (–9.38 kcal/mol) at ALK-5’s active site and the highest kinase inhibition (ATP transfer: 3.67%), outperforming quercetin (9.22%). It also demonstrated an IC50 of 14.92 ± 3.54 μM. Ten flavonols exhibited strong cytotoxicity (GI50 < 10 μM), while four others showed moderate activity (GI50 = 23-26 μM). Discussion: RFL-1 and related flavonols (RFL-12, RFL-20, RFL-25, RFL-28) effectively inhibited ALK-5 and suppressed the growth of pancreatic cancer cells. Their dual activity supports further development as targeted anti-cancer agents. Conclusion: Synthetic flavonols, particularly RFL-1, show promise as ALK-5 inhibitors and potential therapies for pancreatic adenocarcinoma, warranting further in vivo validation. conclusion: A) Flavonols were designed, synthesized and ADP-Glo™ Kinase Inhibition Assay was performed on Transforming Growth factor-β Receptor 1 (TGF- βR1)/ ALK -5, which was found to be up-regulated in Pancreatic cancer. B) The Synthesized novel flavonols were explored for their anti-pancreatic potential on MiaPaCa 2 cell lines, resulting in 10 flavonols having GI50 <10 C) Flavonol RFL-1 exhibited stronger inhibitory effects on ALK-5, lower IC50 value and excellent anti-pancreatic cancer potential, compared to the standard Adriamycin and Quercetin.
No takes yet. Share an insight, caveat, or question.
Cordeiro et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: